---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003356"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:05:23.239002+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports FY2021 net loss $35.5M, IND cleared for DT-216 Phase 1 trial

## Summary
- Net loss $35.5M for FY2021 ($11.1M in Q4); cash and investments $384.1M at Dec 31, 2021.
- IND for DT-216 (Friedreich Ataxia) cleared by FDA; Phase 1 trial to begin shortly.
- Appointed Dr. Jae Kim as Chief Medical Officer to lead clinical development.
- Preclinical data on GeneTAC molecules for Fuchs endothelial corneal dystrophy to be presented at ARVO May 2022.

## SEC filing metadata
- accession: 0000950170-22-003356
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017022003356/0000950170-22-003356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017022003356/dsgn-20220310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003356
- JSON: https://secwatch.observer/filing/0000950170-22-003356.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003356.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.